A Ludwig Cancer Research study has identified a specific mode of fat uptake by immune cells within tumors that serves as a ...

The company plans to introduce Beyfortus, which contains the monoclonal antibody nirsevimab, in a prefilled injection used ...

PF-08052666 was designed to address the limitations of earlier anti-MSLN ADCs through a novel antibody, differentiated linker ...

Today, as we mark World Malaria Day, we're highlighting innovative approaches that can drive progress toward eliminating this ...

Animal testing requirements for monoclonal antibodies and other medications will be “reduced, refined or potentially replaced ...

Nona Biosciences, a global biotechnology company providing integrated solutions from 'Idea to IND' (I to ITM), today ...

Approval of penpulimab-kcqx marks the company’s US regulatory debut and introduces a new immunotherapy option for advanced ...

Key treatments for Alzheimer’s, rare cancers, and infectious diseases are under review, with new vaccines and therapies like ...

But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO ...

Anti-IL1RAP ADC demonstrated potent anti-tumor efficacy and was well tolerated in pre-clinical modelsAnti-IL1RAP ADC targets IL1RAP, which is overexpressed in many tumors and their tumor microenvironm ...

Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein ...

"IL1RAP is an attractive target from an ADC perspective and the data presented show that conjugation of a toxic payload to an anti-IL1RAP antibody ... into new IL1RAP-based therapies", said ...